Mattingly is an associate professor and vice chair of research in the Department of Pharmacotherapy at the University of Utah ...

The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...

Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in ...

On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...

The FTC study examines the practices of PBMs to ensure fair competition and transparency. The FTC found that from 2017 to 2022, the three big PBMs imposed substantial price markups on 51 specialty ...

CVS Caremark, Express Scripts and OptumRx dramatically mark up specialty generic drugs to affiliated pharmacies, the Federal ...

According to the American Diabetes Association, approximately 8.4 million people in the United States need insulin to survive ...

UnitedHealth's CEO acknowledged discontent with the health care system, but quickly shifted the blame elsewhere.

The nation's three largest pharmacy benefit managers have significantly marked up the prices of certain medicines, including ...

From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 ...

The decision by Trump’s team to tap Heather Flick as HHS chief of staff signals an effort to keep closer watch on the ...

Complex PBM money channels “make it hard to build ... and soon hopes to have a sort of “private reserve” of 70 to 80 products that it can make on short notice if they go into shortage ...